X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

CIZ

Cizzle Biotechnology secures US patent allowance for CIZ1B lung cancer biomarker test

Cizzle Biotechnology says the USPTO has allowed a patent application covering core methods used to measure its CIZ1B biomarker for early-stage lung cancer detection...
VRCI

Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

Verici Dx has completed its WRAP Retail Offer, raising approximately £0.19 million in additional gross proceeds and increasing total proceeds to about £2.6 million...
GSK

GSK receives orphan designations for momelotinib in VEXAS syndrome

GSK has received orphan drug designations for momelotinib in the US and EU for VEXAS syndrome, with phase II/III development planned...
Cizzle Biotechnology Holdings plc

Cizzle Bio targets a clear need in lung cancer screening

Cizzle Bio is advancing its CIZ1B blood test as a complementary tool designed to support earlier lung cancer detection and risk assessment...
BIOG

Biotech Growth Trust reports strong one-year performance

Biotech Growth Trust PLC reported a 1-year NAV total return of 87.3% and share price total return of 82.7%, ahead of the benchmark’s 47.4%. Longer-term results were mixed, with 5-year..
EDX Medical Group plc

EDX Medical backs large-scale prostate cancer testing in Scotland

EDX Medical is supporting a Scottish prostate cancer testing programme for 25,000 men, strengthening its position in early cancer detection and practical diagnostic services...
Genflow Biosciences Plc

Genflow Biosciences targets longevity market with gene therapy approach

Genflow Biosciences is positioning its SIRT6 gene therapy platform within the growing longevity biotech sector, where investors are increasingly focused on clinical evidence and clear development pathways...
BIOG

Biotech Growth Trust benefits as small-cap biotech bets pay off

Biotech Growth Trust delivered a strong year as its exposure to smaller biotech companies benefited from improved sentiment, a better interest-rate backdrop and rising takeover activity...
BIOG

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

Biotech Growth Trust notes GSK’s agreed $10.6bn cash acquisition of Nuvalent, a BIOG portfolio company focused on targeted cancer therapies...
VRCI

Verici Dx publishes Circular and Notice of General Meeting

Verici Dx has published a circular convening a general meeting on 22 June 2026 to seek authority to issue new ordinary shares on a non-pre-emptive basis following its recent fundraising...
ETHY

Ethtry reaches 1,000 ETH following further Ethereum purchase

Ethtry PLC has purchased an additional 75 ETH for £93,750, bringing its fully staked Ethereum treasury to 1,000 ETH as part of its ongoing treasury strategy...
BIOG

Why biotech’s next phase is becoming more investable

Biotech investment interest is being supported by pharma patent pressures, renewed capital flows and breakthrough science creating new opportunities for scalable companies...
Ethtry plc

Ethtry offers investors listed exposure to Ethereum treasury growth

Ethtry is positioning itself as a listed route into Ethereum treasury exposure, with formal custody, governance and reporting controls...
Verici Dx Plc

Verici Dx strengthens clinical case for kidney transplant risk testing

Verici Dx has strengthened the clinical evidence behind its pre-transplant kidney rejection risk test, supporting its investor case in precision transplant diagnostics...
VRCI

Verici Dx launches £200,000 WRAP Retail Offer

Verici Dx has opened a WRAP Retail Offer to raise up to £200,000 through new ordinary shares priced at 0.35 pence each, alongside its recently announced £2.5 million placing...
VRCI

Verici Dx raises £2.5m through placing

Verici Dx has completed a placing of 700 million shares at 0.35p each, raising gross proceeds of about £2.5 million to support its organ transplant diagnostics business...
GENF

Genflow Biosciences to hold AGM on 29 June 2026

Genflow Biosciences Plc will hold its Annual General Meeting at 11am on Monday 29 June 2026 at One Heddon Street, London. The Notice of AGM, Form of Proxy, and 2025..
EDX Medical Group plc

AIM admission marks new phase for EDX Medical’s diagnostic expansion

EDX Medical has joined AIM as it advances the commercial rollout of diagnostic tests targeting cancer and other major diseases, supported by growing clinical screening programmes...
Cizzle Biotechnology Holdings plc

Cizzle Bio backs cancer research award linked to early detection focus

Cizzle Bio highlights a cancer research award connected to biomarker science, early detection and better patient outcomes...
ETHY

Ethtry purchases additional 108 ETH under treasury strategy

Ethtry PLC has acquired a further 108.3253 ETH for approximately £162,488, increasing its total Ethereum holdings to 925 ETH as part of its ongoing treasury strategy...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

CIZ

Cizzle Biotechnology secures US patent allowance for CIZ1B lung cancer biomarker test

Cizzle Biotechnology says the USPTO has allowed a patent application covering core methods used to measure its CIZ1B biomarker for early-stage lung cancer detection...
VRCI

Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

Verici Dx has completed its WRAP Retail Offer, raising approximately £0.19 million in additional gross proceeds and increasing total proceeds to about £2.6 million...
GSK

GSK receives orphan designations for momelotinib in VEXAS syndrome

GSK has received orphan drug designations for momelotinib in the US and EU for VEXAS syndrome, with phase II/III development planned...
Cizzle Biotechnology Holdings plc

Cizzle Bio targets a clear need in lung cancer screening

Cizzle Bio is advancing its CIZ1B blood test as a complementary tool designed to support earlier lung cancer detection and risk assessment...
BIOG

Biotech Growth Trust reports strong one-year performance

Biotech Growth Trust PLC reported a 1-year NAV total return of 87.3% and share price total return of 82.7%, ahead of the benchmark’s 47.4%. Longer-term results were mixed, with 5-year NAV growth of 9.4% versus 33.6% for the benchmark...
EDX Medical Group plc

EDX Medical backs large-scale prostate cancer testing in Scotland

EDX Medical is supporting a Scottish prostate cancer testing programme for 25,000 men, strengthening its position in early cancer detection and practical diagnostic services...
Genflow Biosciences Plc

Genflow Biosciences targets longevity market with gene therapy approach

Genflow Biosciences is positioning its SIRT6 gene therapy platform within the growing longevity biotech sector, where investors are increasingly focused on clinical evidence and clear development pathways...
BIOG

Biotech Growth Trust benefits as small-cap biotech bets pay off

Biotech Growth Trust delivered a strong year as its exposure to smaller biotech companies benefited from improved sentiment, a better interest-rate backdrop and rising takeover activity...
BIOG

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

Biotech Growth Trust notes GSK’s agreed $10.6bn cash acquisition of Nuvalent, a BIOG portfolio company focused on targeted cancer therapies...
VRCI

Verici Dx publishes Circular and Notice of General Meeting

Verici Dx has published a circular convening a general meeting on 22 June 2026 to seek authority to issue new ordinary shares on a non-pre-emptive basis following its recent fundraising...
ETHY

Ethtry reaches 1,000 ETH following further Ethereum purchase

Ethtry PLC has purchased an additional 75 ETH for £93,750, bringing its fully staked Ethereum treasury to 1,000 ETH as part of its ongoing treasury strategy...
BIOG

Why biotech’s next phase is becoming more investable

Biotech investment interest is being supported by pharma patent pressures, renewed capital flows and breakthrough science creating new opportunities for scalable companies...
Ethtry plc

Ethtry offers investors listed exposure to Ethereum treasury growth

Ethtry is positioning itself as a listed route into Ethereum treasury exposure, with formal custody, governance and reporting controls...
Verici Dx Plc

Verici Dx strengthens clinical case for kidney transplant risk testing

Verici Dx has strengthened the clinical evidence behind its pre-transplant kidney rejection risk test, supporting its investor case in precision transplant diagnostics...
VRCI

Verici Dx launches £200,000 WRAP Retail Offer

Verici Dx has opened a WRAP Retail Offer to raise up to £200,000 through new ordinary shares priced at 0.35 pence each, alongside its recently announced £2.5 million placing...
VRCI

Verici Dx raises £2.5m through placing

Verici Dx has completed a placing of 700 million shares at 0.35p each, raising gross proceeds of about £2.5 million to support its organ transplant diagnostics business...
GENF

Genflow Biosciences to hold AGM on 29 June 2026

Genflow Biosciences Plc will hold its Annual General Meeting at 11am on Monday 29 June 2026 at One Heddon Street, London. The Notice of AGM, Form of Proxy, and 2025 Annual Report are available on the company’s website...
EDX Medical Group plc

AIM admission marks new phase for EDX Medical’s diagnostic expansion

EDX Medical has joined AIM as it advances the commercial rollout of diagnostic tests targeting cancer and other major diseases, supported by growing clinical screening programmes...
Cizzle Biotechnology Holdings plc

Cizzle Bio backs cancer research award linked to early detection focus

Cizzle Bio highlights a cancer research award connected to biomarker science, early detection and better patient outcomes...
ETHY

Ethtry purchases additional 108 ETH under treasury strategy

Ethtry PLC has acquired a further 108.3253 ETH for approximately £162,488, increasing its total Ethereum holdings to 925 ETH as part of its ongoing treasury strategy...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple